Brazil in the Global Regulatory Landscape
Brazil's medical device regulatory system — led by ANVISA — is one of the largest and most sophisticated in the Americas, and one of the most important markets for manufacturers seeking to expand beyond the EU, US, and other mature markets.
Brazil's position
| Feature | Detail |
|---|---|
| Market size | 6th largest medical device market globally (by value, est. 2025) |
| Regulatory authority | ANVISA (federal), state VISA, municipal VISA |
| IMDRF member | Yes — full voting member since 2020 |
| MERCOSUL member | Yes — founding member; medical device regulations harmonised with Argentina, Uruguay, Paraguay |
| ISO 13485 acceptance | Yes — accepted for foreign manufacturer GMP compliance |
| UDI implementation | In progress — aligned with IMDRF framework |
Key strengths of the Brazilian regulatory framework
- Risk-based classification aligned with IMDRF and MERCOSUL
- Online submission via Peticionamento Eletrônico
- 10-year registration validity
- Active participation in IMDRF working groups
- Growing alignment with ISO standards and international GCP
Key challenges
- Long review timelines for Class III/IV Registro (12–36 months)
- Portuguese language requirement for all labelling and submissions
- Three-tier regulatory system (federal + state + municipal) adds complexity
- Importer as registration holder model: Foreign manufacturers must appoint a Brazilian legal entity (importer/distributor) as the registration holder, creating additional compliance obligations and reliance on third-party representation
- AFE (Establishment Authorisation) requirement: All manufacturers and importers must obtain an AFE certificate (Certificado de Autorização de Funcionamento) before commercialising devices, adding and timeline compliance cost
Official resources
Official sources
Verify all information against official ANVISA sources before making regulatory decisions.
Current regulatory framework: Medical device registration is governed by RDC 751/2022 (replacing RDC 185/2001), which aligns Brazil's requirements with IMDRF standards and ISO 13485. The regulation is supported by four companion RDCs covering GMP (RDC 752/2022), adverse events (RDC 753/2022), labelling (RDC 754/2022), and establishment authorisation (RDC 755/2022).